Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations

NCT ID: NCT00004694

Last Updated: 2015-03-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1994-01-31
• Study Completion Date: 1998-09-30

Brief Summary

OBJECTIVES:

I. Determine the safety and efficacy of inhaled and subcutaneously administered heparin in the treatment of hereditary angioedema.

Detailed Description

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, 3 way crossover study.

All patients complete diary cards for the first month of the study in order to determine compliance in providing a daily record of symptoms and medication taken. All compliant patients receive subcutaneously injected heparin twice daily, inhaled heparin daily, or matched saline placebo in a random order. Each of the three drug administration periods lasts 2 months, for a total of 6 months of treatment. Patients who have a flare in disease activity that requires hospitalization are terminated from that drug administration period of the study.

Patients are followed biweekly during the first month and again at the end of the second month for each of the three 2 month drug administration periods.

Completion date provided represents the completion date of the grant per OOPD records

Conditions

Angioedema

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Interventions

heparin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

• Confirmed diagnosis of hereditary angioedema (HAE) based upon C4 antigenic level, positive family history, and C1 inhibitor (C1INH) antigenic level (Type I HAE) or functional level (Type II HAE)
• Functional C1 within normal levels if diagnosis of acquired C1INH is possible
• Negative family history will not exclude as long as patient meets all other criteria, has normal C1 level, and has no evidence of acquired C1INH deficiency
• History of symptoms of HAE including episodic swelling, abdominal pain, and/or respiratory difficulty
• Experiencing a minimum of 1-2 HAE episodes within 6 weeks

--Prior/Concurrent Therapy--

• Endocrine therapy: Anabolic steroids allowed as long as dose has not been changed in at least 30 days
• Other: No concurrent and at least 1 week since prior aspirin, nonsteroidal antiinflammatory agents, dipyridamole, Coumadin-like drugs, or any other medication having an effect on coagulation or platelets

--Patient Characteristics--

• Hematopoietic: No clinically significant history of hematologic disease
• Hepatic: No clinically significant history of hepatic disease
• Renal: No clinically significant history of renal disease
• Cardiovascular: No clinically significant history of cardiac disease or hypertension
• Pulmonary: No clinically significant history of pulmonary disease
• Other: No contraindication to the use of inhaled or subcutaneous heparin No drug allergy that would interfere with the study No clinically significant history of: Malignancy Diabetes mellitus Neurologic disease Immunologic disease Bleeding disorder Infirmity No history of drug abuse, alcoholism, psychosis, or other psychological/psychiatric disorder

• Minimum Eligible Age: 8 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Iowa

OTHER

Sponsor Role: lead

Principal Investigators

John M. Weiler

Role: STUDY_CHAIR

University of Iowa

Other Identifiers

UI-9311397

Identifier Type: -

Identifier Source: secondary_id

UI-FDR001001

Identifier Type: -

Identifier Source: secondary_id

199/13356

Identifier Type: -

Identifier Source: org_study_id